Regeneron Pharmaceuticals Inc. buy Lars
Start price
08.11.21
/
50%
€524.70
Target price
08.11.22
-
Performance (%)
10.50%
End price
21.07.22
€579.80
Summary
This prediction ended on 21.07.22 with a price of €579.80. The prediction had a final performance of 10.50%. Lars has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | 2.524% | 2.524% | 41.136% | -3.651% |
| iShares Core DAX® | 2.573% | 3.502% | 8.408% | 62.272% |
| iShares Nasdaq 100 | 4.858% | 0.654% | 28.383% | 85.454% |
| iShares Nikkei 225® | 5.590% | -0.246% | 52.915% | 76.580% |
| iShares S&P 500 | 3.250% | 2.083% | 24.370% | 68.715% |
Comments by Lars for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Lars hat das Wertpapier Regeneron Pharmaceuticals Inc. in seinem Wikifolio Wikifolio WF00074737 von Lars gekauft.